Fate therapeutics presents pan-tumor targeting preclinical data for ft836 mica/b-targeted car t-cell product candidate at 2024 sitc annual meeting

Multiplexed-engineered, ipsc-derived car t cell targets proteins expressed on cancer cells in response to cellular stress and malignant transformation

CAR Ratings Summary

CAR Quant Ranking